AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 14 - (NewsRx.com & NewsRx.net) --
- by Michelle Marble, staff medical writer -- Researchers in Brazil, seeking a new vaccine against diphtheria, pertussis, and tetanus (DPT), put a mutant twist on the old and reliable bacillus Calmette-Guerin (BCG) vaccine.
"BCG, the attenuated strain of Mycobacterium bovis, has been widely used as a vaccine against tuberculosis and is thus an important candidate as a live carrier for multiple antigens," wrote Eliane N. Miyaji and colleagues from the Instituto Butantan, Sao Paulo. "With the aim of developing a recombinant BCG (rBCG) vaccine against DPT, we analyzed the potential of CRM197, a mutated nontoxic derivative of diphtheria toxin, as the recombinant antigen for a BCG-based vaccine against diphtheria."
Miyaji et al. published their study in the journal Infection and Immunity ("Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM197, a mutant diphtheria toxin," Infect and Immun, February 2001;69(2):869-874).
The researchers used Escherichia coli-Mycobacterium shuttle vectors under the control of pBlaF*, an upregulated-lactamase promoter from M. fortuitum to express CRM197 in rBCG. Mice were immunized with rBCG-CRM197.
The immunized mice elicited an anti-diphtheria toxoid antibody response. Despite this, the sera of the mice were not able to neutralize diphtheria toxin (DTx) activity, reported Miyaji et al.
Another group of mice was inoculated with a sub-immunizing dose of the conventional diphtheria-tetanus vaccine in order to mimic an ...